Innovative Solutions to Serious Health Problems.

Many Problems. A Multitarget Solution.

SG1002 A Novel Hydrogen Sulfide Prodrug

Hydrogen sulfide (H2S) has recently emerged as a critical gaseous component playing a major role in normal
physiology and pathophysiology.

Via the action of cysteine metabolic enzymes, it is naturally generated at low micromolar levels in the heart, liver,
kidney, brain, nervous system, lung, airway tissues, gastrointestinal tract, reproductive organs, skeletal muscle,
pancreas, synovial joints, connective tissue, cochlea and adipose tissues of all mammalian species.

Cardiometabolic Disease

Viral Infections

Neurodegeneration & Neuropathic Pain

Reproductive Function

Skin Disease/Wound & Skin Ulcer Healing/Skin Transplantation

Ophthalmic Disease


SG1002 AND COVID-19 (UPDATE: 05 MAY,2020)

The Creator of Sulfagenix

Leadership in Sodium Polysulthionate Research

Dr. Gojon, a past recipient of the prestigious Andres Manuel del Rio award (2007) from the National Chemical Society Mexico, is the Chief Scientific Officer and co-founder of Sulfagenix and the co-discoverer of SG1002. 


What We Do?


The Sulfagenix Solution

Sulfagenix holds the key unlocking the regenerating abilities of the body 
SG1002 (sodium polysulthionate), Sulfagenix’s clinical-stage prodrug, is a precursor to a natural-occurring molecule, hydrogen sulfide, for which deficits have been shown to exist in a number of serious diseases, including cardiovascular disease.
Sulfagenix, Inc. is built on decades of research on modifying existing molecules to improve safety, bioavailability and efficacy for new uses.

Need help?

      MX +52 (81) 1936 4400

      US +1 (520) 329 2517


Follow our company to be the first to get the news.

  • Facebook
  • Twitter

USA Address

3561 E Sunrise Dr, Ste 131

Tucson, Arizona, USA 85718

Mexico Address

Av. Ricardo Margain 440, Torre Sofía Of. 602

San Pedro Garza Garcia, N.L., Mexico 66265